These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22465920)

  • 21. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
    Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
    Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
    Tatematsu S; Wakino S; Kanda T; Homma K; Yoshioka K; Hasegawa K; Sugano N; Kimoto M; Saruta T; Hayashi K
    J Am Soc Nephrol; 2007 Mar; 18(3):741-9. PubMed ID: 17267746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH
    Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
    Toutouzas K; Riga M; Stefanadi E; Stefanadis C
    Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The endothelium as a target in renal diseases.
    Zoccali C
    J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
    Böger RH; Zoccali C
    Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.
    Dimitroulas T; Sandoo A; Kitas GD
    Int J Mol Sci; 2012 Sep; 13(10):12315-35. PubMed ID: 23202900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
    Chan NN; Chan JC
    Diabetologia; 2002 Dec; 45(12):1609-16. PubMed ID: 12488950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease.
    Sahin M; Arslan C; Naziroglu M; Tunc SE; Demirci M; Sutcu R; Yilmaz N
    Ann Clin Lab Sci; 2006; 36(4):449-54. PubMed ID: 17127734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
    Böger RH; Ron ES
    Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
    Sydow K; Mondon CE; Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
    Tan B; Jiang DJ; Huang H; Jia SJ; Jiang JL; Hu CP; Li YJ
    Vascul Pharmacol; 2007 May; 46(5):338-45. PubMed ID: 17293168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of the factors of hypoxia and endothelial dysfunction in kidney injury in the presence of obesity].
    Galiamov MG; Saginova EA; Severova MM; Samokhodskaia LM; Krasnova TN; Sholomova VI; Sorokin IuD; Mukhin NA
    Ter Arkh; 2013; 85(6):31-7. PubMed ID: 23866596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of asymmetric dimethylarginine in cardiorenal syndrome.
    Ueda S; Yamagishi S; Yokoro M; Okuda S
    Curr Pharm Des; 2014; 20(14):2448-55. PubMed ID: 23844812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.
    Landim MB; Casella Filho A; Chagas AC
    Clinics (Sao Paulo); 2009 May; 64(5):471-8. PubMed ID: 19488614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
    Ivanova M; Artusi C; Boffa GM; Zaninotto M; Plebani M
    Clin Chim Acta; 2010 Nov; 411(21-22):1632-6. PubMed ID: 20542018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.